Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ana Xavier-Magalhães is active.

Publication


Featured researches published by Ana Xavier-Magalhães.


Molecular Cancer Research | 2016

Understanding TERT Promoter Mutations: A Common Path to Immortality.

Robert J.A. Bell; H. Tomas Rube; Ana Xavier-Magalhães; Bruno M. Costa; Andrew Mancini; Jun S. Song; Joseph F. Costello

Telomerase (TERT) activation is a fundamental step in tumorigenesis. By maintaining telomere length, telomerase relieves a main barrier on cellular lifespan, enabling limitless proliferation driven by oncogenes. The recently discovered, highly recurrent mutations in the promoter of TERT are found in over 50 cancer types, and are the most common mutation in many cancers. Transcriptional activation of TERT, via promoter mutation or other mechanisms, is the rate-limiting step in production of active telomerase. Although TERT is expressed in stem cells, it is naturally silenced upon differentiation. Thus, the presence of TERT promoter mutations may shed light on whether a particular tumor arose from a stem cell or more differentiated cell type. It is becoming clear that TERT mutations occur early during cellular transformation, and activate the TERT promoter by recruiting transcription factors that do not normally regulate TERT gene expression. This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation. These somatic promoter mutations, along with germline variation in the TERT locus also appear to have significant value as biomarkers of patient outcome. Understanding the precise molecular mechanism of TERT activation by promoter mutation and germline variation may inspire novel cancer cell-specific targeted therapies for a large number of cancer patients. Mol Cancer Res; 14(4); 315–23. ©2016 AACR.


Journal of Neuro-oncology | 2017

Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis

Ana Xavier-Magalhães; Ana Isabel Oliveira; Joana Vieira de Castro; Marta Pojo; Céline S. Gonçalves; Tatiana Lourenço; Marta Viana-Pereira; Sandra Costa; Paulo Linhares; Rui Vaz; Rui Nabiço; Júlia Amorim; Afonso A. Pinto; Rui M. Reis; Bruno M. Costa

Abnormal expression of the long non-coding RNA HOX transcript antisense intergenic RNA (HOTAIR) is oncogenic in several human cancers, including gliomas. The HOTAIR single nucleotide polymorphisms (SNPs) rs920778 (C > T) and rs12826786 (C > T) present in the intronic enhancer and promoter regions of HOTAIR, respectively, are associated with expression, cancer susceptibility, and patient prognosis in some tumor types. However, the relevance of these HOTAIR SNPs has not been studied in glioma. Here, we report a case-control study comprising 177 Portuguese glioma patients and 199 cancer-free controls. All subjects were genotyped by PCR and restriction fragment length polymorphism (RFLP). No statistically significant differences were found in the genotype or allele distributions of either rs920778 or rs12826786 between glioma patients and controls, suggesting these SNPs are not associated with glioma risk. No significant associations were found between rs920778 variants and HOTAIR expression levels, while rs12826786 CT genotype was associated with increased intratumoral HOTAIR RNA levels when compared to TT genotype (p-value = 0.04). Univariate (Log-rank) and multivariate (Cox proportional) analyses showed both rs920778 CT and rs12826786 CT genotypes were significantly associated with longer overall survival of WHO grade III anaplastic oligodendroglioma patients. Our results suggest that HOTAIR SNPs rs920778 and rs12826786 do not play a significant role in glioma susceptibility, but may be important prognostic factors in anaplastic oligodendroglioma patients. Future studies are warranted to validate and expand these findings, and to further dissect the importance of these SNPs in glioma.


CNS oncology | 2013

Molecular prognostic factors in glioblastoma: state of the art and future challenges

Ana Xavier-Magalhães; Meera Nandhabalan; Chris Jones; Bruno M. Costa

Gliomas account for the majority of primary tumors of the CNS, of which glioblastoma (GBM) is the most common and malignant, and for which survival is very poor. Despite significant inter- and intra-tumor heterogeneity, all patients are treated with a standardized therapeutic approach. While some clinical features of GBM patients have already been established as classic prognostic factors (e.g., patient age at diagnosis and Karnofsky performance status), one of the most important research fields in neuro-oncology today is the identification of novel molecular determinants of patient survival and tumor response to therapy. Here, we aim to review and discuss some of the most relevant and novel prognostic biomarkers in adult and pediatric GBM patients that may aid in stratifying subgroups of GBMs and rationalizing treatment decisions.


Cancer Cell | 2018

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner

Andrew Mancini; Ana Xavier-Magalhães; Wendy S. Woods; Kien-Thiet Nguyen; Alexandra M. Amen; Josie Hayes; Christof Fellmann; Michael Gapinske; Andrew McKinney; Chibo Hong; Lindsey Jones; Kyle M. Walsh; Robert J.A. Bell; Jennifer A. Doudna; Bruno M. Costa; Jun S. Song; Pablo Perez-Pinera; Joseph F. Costello

TERT promoter mutations reactivate telomerase, allowing for indefinite telomere maintenance and enabling cellular immortalization. These mutations specifically recruit the multimeric ETS factor GABP, which can form two functionally independent transcription factor species: a dimer or a tetramer. We show that genetic disruption of GABPβ1L (β1L), a tetramer-forming isoform of GABP that is dispensable for normal development, results in TERT silencing in a TERT promoter mutation-dependent manner. Reducing TERT expression by disrupting β1L culminates in telomere loss and cell death exclusively in TERT promoter mutant cells. Orthotopic xenografting of β1L-reduced, TERT promoter mutant glioblastoma cells rendered lower tumor burden and longer overall survival in mice. These results highlight the critical role of GABPβ1L in enabling immortality in TERT promoter mutant glioblastoma.


Oncotarget | 2018

The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma

Ana Xavier-Magalhães; Céline S. Gonçalves; Anne Fogli; Tatiana Lourenço; Marta Pojo; Bruno Pereira; Miguel Rocha; Maria Celeste Lopes; Inês Crespo; Olinda Rebelo; Hermínio Tão; João Paulo da Silveira Nogueira Lima; Ricardo Moreira; Afonso A. Pinto; Chris Jones; Rui M. Reis; Joseph F. Costello; Philippe Arnaud; Nuno Sousa; Bruno M. Costa

The lncRNA HOTAIR has been implicated in several human cancers. Here, we evaluated the molecular alterations and upstream regulatory mechanisms of HOTAIR in glioma, the most common primary brain tumors, and its clinical relevance. HOTAIR gene expression, methylation, copy-number and prognostic value were investigated in human gliomas integrating data from online datasets and our cohorts. High levels of HOTAIR were associated with higher grades of glioma, particularly IDH wild-type cases. Mechanistically, HOTAIR was overexpressed in a gene dosage-independent manner, while DNA methylation levels of particular CpGs in HOTAIR locus were associated with HOTAIR expression levels in GBM clinical specimens and cell lines. Concordantly, the demethylating agent 5-Aza-2′-deoxycytidine affected HOTAIR transcriptional levels in a cell line-dependent manner. Importantly, HOTAIR was frequently co-expressed with HOXA9 in high-grade gliomas from TCGA, Oncomine, and our Portuguese and French datasets. Integrated in silico analyses, chromatin immunoprecipitation, and qPCR data showed that HOXA9 binds directly to the promoter of HOTAIR. Clinically, GBM patients with high HOTAIR expression had a significantly reduced overall survival, independently of other prognostic variables. In summary, this work reveals HOXA9 as a novel direct regulator of HOTAIR, and establishes HOTAIR as an independent prognostic marker, providing new therapeutic opportunities to treat this highly aggressive cancer.


Biomarkers in Medicine | 2018

Influence of HOTAIR rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival

Ana Isabel Oliveira; Ana Xavier-Magalhães; Catarina Moreira-Barbosa; Hugo Magalhães; Rui Henrique; Carmen Jerónimo; Bruno M. Costa

AIM Evaluate the impact of the single nucleotide polymorphisms rs920778 and rs12826786 in the long noncoding RNA HOTAIR in the susceptibility and prognosis of prostate cancer (PCa) patients. PATIENTS & METHODS HOTAIR single nucleotide polymorphisms were genotyped by restriction fragment length polymorphism in 151 PCa cases and 180 cancer-free controls. Odds ratio, 95% CIs and prognostic significance were calculated. RESULTS Our data showed no statistically significant associations between HOTAIR polymorphic variants in rs920778 and rs12826786 and PCa susceptibility. However, the CC genotype in rs12826786 was significantly associated with shorter biochemical recurrence-free survival in pT3-stage PCa patients. CONCLUSION Our results indicate that HOTAIR rs12826786 CC genotype may be an independent prognostic biomarker in a particular subset of PCa tumors.


Oncotarget | 2015

A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide

Marta Pojo; Céline S. Gonçalves; Ana Xavier-Magalhães; Ana Isabel Oliveira; Tiago Cúrdia Gonçalves; Sara Correia; Ana João Rodrigues; Sandra Costa; Luísa Pinto; Afonso A. Pinto; José Manuel Lopes; Rui M. Reis; Miguel Rocha; Nuno Sousa; Bruno M. Costa


Journal of Nanoparticle Research | 2013

In vitro evaluation of the cytotoxicity and cellular uptake of CMCht/PAMAM dendrimer nanoparticles by glioblastoma cell models

Marta Pojo; S. R. Cerqueira; T. Mota; Ana Xavier-Magalhães; S. Ribeiro-Samy; João F. Mano; Joaquim M. Oliveira; Rui L. Reis; Nuno Sousa; Bruno M. Costa; António J. Salgado


European Journal of Cancer | 2016

Regulation of WNT6 by HOXA9 in glioblastoma: functional and clinical relevance

Clemente José Gonçalves; Marta Pojo; Ana Xavier-Magalhães; J. Vieira de Castro; Armando Pinto; Ricardo Taipa; Fernando Pardal; Rui M. Reis; Nuno Sousa; Bruno M. Costa


Neuro-oncology | 2017

CSIG-38. REVERSAL OF GLIOBLASTOMA REPLICATIVE IMMORTALITY IN A TERT PROMOTER MUTATION-DEPENDENT MANNER

Andrew Mancini; Ana Xavier-Magalhães; Wendy S. Woods; Kien-Thiet Nguyen; Alexandra M. Amen; Andrew McKinney; Josie Hayes; Jun S. Song; Bruno M. Costa; Pablo Perez-Pinera; Joseph F. Costello

Collaboration


Dive into the Ana Xavier-Magalhães's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew Mancini

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge